{
  "id": "enwiki-001366153127",
  "slug": "jerini",
  "title": "Jerini",
  "qid": "",
  "lead": "Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008. Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH, provider of peptides and peptide microarrays, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with venture capital provided by TVM and HealthCap. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date.",
  "body": "Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008. Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH, provider of peptides and peptide microarrays, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with venture capital provided by TVM and HealthCap. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date. ==Firazyr (icatibant)== Jerini's lead compound Firazyr (icatibant), is an inhibitor of the action of the hormone bradykinin on its B2 receptor. This compound was in-licensed from Aventis in 2001. It has been approved for hereditary angioedema in all member states of the European Union in July 2008. The drug was granted FDA approval on August 25, 2011. ==References== ==External links== Official website JPT Peptide Technologies European HAE information portal",
  "categories": [
    "129826521",
    "20462679",
    "20605351",
    "21493616",
    "22923484",
    "22963339",
    "23118434",
    "23603337",
    "24745122",
    "37645845",
    "5944526",
    "6438746",
    "7382403",
    "80649061",
    "9567816",
    "9620104"
  ],
  "license": "CC BY-SA 4.0",
  "source_uri": "https://en.wikipedia.org/w/index.php?oldid=1366153127",
  "content_hash": "",
  "created_at": null,
  "updated_at": 1785075318.0,
  "claims": [],
  "contradictions": [],
  "confidence": 0.6,
  "csl": {
    "id": "enwiki-001366153127",
    "type": "webpage",
    "title": "Jerini",
    "author": [
      {
        "family": "Anticloud FZ LLE",
        "literal": "Anticloud FZ LLE"
      }
    ],
    "container-title": "encyclopegia.org",
    "publisher": "Anticloud FZ LLE",
    "publisher-place": "Dubai, United Arab Emirates",
    "URL": "https://encyclopegia.org/a/jerini",
    "issued": {
      "date-parts": [
        [
          2026,
          11,
          20
        ]
      ]
    },
    "accessed": {
      "date-parts": [
        [
          2026,
          11,
          20
        ]
      ]
    },
    "license": "CC BY-SA 4.0",
    "DOI": "eo1:enwiki-001366153127",
    "isBasedOn": "https://en.wikipedia.org/w/index.php?oldid=1366153127",
    "note": "Immutable snapshot enwiki-001366153127"
  }
}